The approval of Roche’s Itovebi marks a pivotal moment in breast cancer care, with the potential to significantly alter treatment strategies for ER-positive, HER2-negative breast cancer patients with PIK3CA mutations. The regulatory green light indicates a promising shift in oncology, specifically
In the world of biopharmaceuticals and immunotherapy, Ivan Kairatov stands out with his profound expertise. His deep understanding of the latest advancements makes him a perfect candidate to discuss ALK’s Itulazax, a groundbreaking treatment for hay fever caused by birch tree pollen. In this
A transformative wave is sweeping through biomedical science as the regenerative organs market is poised for unprecedented growth, with projections estimating it will reach a valuation of USD 225.18 billion by 2032. This anticipated growth is driven by a compelling combination of factors, most
Imagine a world where Alzheimer's disease can be anticipated years before its debilitating symptoms manifest, allowing for timely intervention that could change the course of an individual’s life. This could soon be a reality, thanks to the groundbreaking work of Dr. Hamilton Se-Hwee Oh, whose
Breast cancer remains a formidable adversary in the field of oncology, with radiotherapy serving as one of its most prevalent treatment modalities. Traditionally, radiotherapy is administered postoperatively to eliminate residual cancer cells and reduce the chances of relapse. Yet, the biological
In today's discussion, we have the pleasure of speaking with Ivan Kairatov, a seasoned Biopharma expert known for his profound insights into the tech and innovation driving the pharmaceutical industry. With extensive experience in research and development, Ivan is here to share his knowledge about
